BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 9168821)

  • 41. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
    Reilly TM; Mousa SA; Seetharam R; Racanelli AL
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrillar collagen regulation of plasminogen activator inhibitor-1 is involved in altered smooth muscle cell migration.
    Tanaka S; Koyama H; Ichii T; Shioi A; Hosoi M; Raines EW; Nishizawa Y
    Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1573-8. PubMed ID: 12377732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response of human osteoblasts to implant materials: integrin-mediated adhesion.
    Gronowicz G; McCarthy MB
    J Orthop Res; 1996 Nov; 14(6):878-87. PubMed ID: 8982129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
    Wei Y; Czekay RP; Robillard L; Kugler MC; Zhang F; Kim KK; Xiong JP; Humphries MJ; Chapman HA
    J Cell Biol; 2005 Jan; 168(3):501-11. PubMed ID: 15684035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors.
    Robson SC; Saunders R; Kirsch RE
    J Clin Lab Immunol; 1990 Oct; 33(2):83-90. PubMed ID: 1967070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding and activation of plasminogen on the surface of osteosarcoma cells.
    Campbell PG; Wines K; Yanosick TB; Novak JF
    J Cell Physiol; 1994 Apr; 159(1):1-10. PubMed ID: 7511144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
    Isogai C; Laug WE; Shimada H; Declerck PJ; Stins MF; Durden DL; Erdreich-Epstein A; DeClerck YA
    Cancer Res; 2001 Jul; 61(14):5587-94. PubMed ID: 11454712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
    Padmanabhan J; Sane DC
    Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of cell adhesion by PAI-1.
    Loskutoff DJ; Curriden SA; Hu G; Deng G
    APMIS; 1999 Jan; 107(1):54-61. PubMed ID: 10190280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TFPI or uPA-PAI-1 complex affect cell function through expression variation of type II very low density lipoprotein receptor.
    Di Y; Liu Z; Tian J; Zong Y; Yang P; Qu S
    FEBS Lett; 2010 Aug; 584(15):3469-73. PubMed ID: 20624392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro.
    Jankun J
    Cancer Res; 1992 Oct; 52(20):5829-32. PubMed ID: 1327517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
    Stahl A; Mueller BM
    Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of plasminogen activator inhibitor-1 as inhibitor of platelet and megakaryoblastic cell adhesion.
    Wohn KD; Schmidt T; Kanse SM; Yutzy B; Germer M; Morgenstern E; Preissner KT
    Br J Haematol; 1999 Mar; 104(4):901-8. PubMed ID: 10192457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin.
    Reinartz J; Schäfer B; Batrla R; Klein CE; Kramer MD
    Exp Cell Res; 1995 Oct; 220(2):274-82. PubMed ID: 7556434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.
    Carriero MV; Franco P; Gargiulo L; Vocca I; Cito L; Fontana L; Iaccarino C; Del Pozzo G; Guardiola J; Stoppelli MP
    Biol Chem; 2002 Jan; 383(1):107-13. PubMed ID: 11928806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of the cell adhesion molecule CHL1 with vitronectin, integrins, and the plasminogen activator inhibitor-2 promotes CHL1-induced neurite outgrowth and neuronal migration.
    Katic J; Loers G; Kleene R; Karl N; Schmidt C; Buck F; Zmijewski JW; Jakovcevski I; Preissner KT; Schachner M
    J Neurosci; 2014 Oct; 34(44):14606-23. PubMed ID: 25355214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.